The Journal for ImmunoTherapy of Cancer
is an open access journal that publishes high quality research, literature reviews, position papers and practice guidelines, and case studies on all components of cancer immunology and immunotherapy.
Impact Factor: 10.9
Citescore: 16.8
All metrics >>
Highlighted Articles
Authors
The Journal for ImmunoTherapy of Cancer accepts a variety of article types in a number of formats.
The Author Information section provides specific article requirements and section outlines to help you turn your research into an article suitable for JITC.
Information is also provided on editorial policy, Open Access fees and formatting.
Latest Articles
Immune cell therapies and immune cell engineering:
Safety and efficacy of SNK01 (autologous natural killer cells) in combination with cytotoxic chemotherapy and/or cetuximab after failure of prior tyrosine kinase inhibitor in non-small cell lung cancer: non-clinical mouse model and phase I/IIa clinical study27 March 2024
Correction:
Correction: High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma27 March 2024
Clinical/translational cancer immunotherapy:
Poor clinical outcomes and immunoevasive contexture in CD161+CD8+ T cells barren human pancreatic cancer27 March 2024
Correction:
Correction: SITC clinical Immuno-Oncology network (SCION) commentary on measurement and interpretation of essential biomarkers in early clinical trials27 March 2024
Clinical/translational cancer immunotherapy:
Impact of immunotherapy time-of-day infusion on survival and immunologic correlates in patients with metastatic renal cell carcinoma: a multicenter cohort analysis27 March 2024
Most Read Articles
Immune cell therapies and immune cell engineering:
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts…13 December 2022
Clinical/translational cancer immunotherapy:
Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial12 February 2024
Immunotherapy biomarkers:
Inflamed immune phenotype predicts favorable clinical outcomes of immune checkpoint inhibitor therapy across multiple cancer types14 February 2024
Altmetrics
What Our Editors Are Reading
In JITC’s Reading List, JITC editors provide a monthly list of publications in other journals that have their attention and add value to what readers may find in JITC. Read what has piqued the interest of this month’s featured editor in the latest Reading List.
About SITC
The Society for Immunotherapy of Cancer (SITC) is the world’s leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. As a way to thank the SITC members who work tirelessly to advance the science and improve the lives of cancer patients, SITC provides members with a 35% discount on Article Processing Charges (APCs) for all JITC articles submitted and accepted in 2023. This discount is applied post-acceptance, at which point a discount code is shared with the corresponding author.
For information on APC discounts and waivers – including those for members, editors or reviewers, low-income countries, or institutional arrangements – view the journal's APC policy.